The report is a “comprehensive educational tool that chronicles the progress that has been made against cancer…and calls on the administration and Congress to prioritize the growth of the NIH and NCI budgets,” according to AACR.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
